Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alere continues pursuit of Axis-Shield with shareholder offer

This article was originally published in Clinica

Executive Summary

In its latest effort to takeover Axis-Shield, Alere has posted an offer document to the company's shareholders. As before, the diagnostics giant is offering 460p per share, which values Axis-Shield at £230m ($375m) in total. In response, Axis-Shield's board, which has already twice rebuffed Alere, issued a statement maintaining that the bid fundamentally undervalues the company and its future prospects. The company said it will write to shareholders setting out its position on Alere's offer by 25 August. Alere has been steadily building its stake in the Anglo-Nordic IVD firm in a bid to put pressure on Axis-Shield's board to agree to a takeover. Alere currently holds 9.09% of the company, making it the second-biggest shareholder after Legal and General (www.clinica.co.uk, 10 August 2011).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT097738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel